Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: AMPA receptor agonists - RespireRx

Drug Profile

Research programme: AMPA receptor agonists - RespireRx

Alternative Names: Ampakines; CX 929; CX1501; CX1763; CX1796; CX1837; CX1846; CX1942; CX2007; CX2076; CX516; CX614; CX707

Latest Information Update: 30 May 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cortex Pharmaceuticals
  • Developer Cortex Pharmaceuticals; RespireRx Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action AMPA receptor agonists; Brain derived neurotrophic factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Respiratory insufficiency
  • No development reported Alzheimer's disease; Anxiety disorders; Attention-deficit hyperactivity disorder; Fragile X syndrome; Huntington's disease; Major depressive disorder; Mild cognitive impairment; Parkinson's disease; Rett syndrome; Schizophrenia; Sleep apnoea syndrome; Spinal cord injuries; Stroke
  • Discontinued Autistic disorder; Chronic brain damage

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for preclinical development in Spinal-cord-injuries in USA (PO)
  • 31 Dec 2017 CX 1942 is still in preclinical trials for Respiratory insufficiency in USA
  • 01 Apr 2016 Preclinical development is ongoing for Spinal cord injuries in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top